[go: up one dir, main page]

BRPI0812919B8 - composição farmacêutica que compreende um composto e kit - Google Patents

composição farmacêutica que compreende um composto e kit

Info

Publication number
BRPI0812919B8
BRPI0812919B8 BRPI0812919A BRPI0812919A BRPI0812919B8 BR PI0812919 B8 BRPI0812919 B8 BR PI0812919B8 BR PI0812919 A BRPI0812919 A BR PI0812919A BR PI0812919 A BRPI0812919 A BR PI0812919A BR PI0812919 B8 BRPI0812919 B8 BR PI0812919B8
Authority
BR
Brazil
Prior art keywords
methods
compound
hypertension
relates
calcium channel
Prior art date
Application number
BRPI0812919A
Other languages
English (en)
Inventor
Rioux Elise
j leighton Harry
P Maguire Martin
Original Assignee
Milestone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Milestone Pharmaceuticals Inc filed Critical Milestone Pharmaceuticals Inc
Publication of BRPI0812919A2 publication Critical patent/BRPI0812919A2/pt
Publication of BRPI0812919B1 publication Critical patent/BRPI0812919B1/pt
Publication of BRPI0812919B8 publication Critical patent/BRPI0812919B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/43—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms the carbon skeleton being further substituted by singly-bound oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

bloqueadores de canal de cálcio de fenilalquilamina de ação curta e uso dos mesmos a presente invenção refere-se ao uso de uma quantidade farmaceuticamente eficaz de um composto cálcio de bloqueio de canal de cálcio de curta ação para tratar condição cardíaca isquêmica, arritmias cardíacas,crise hipertensiva em uma rotina de quarto de emergência, hipertensão antes, durante, ou depois de cirurgia, fenômeno de não-refluxo seguinte a reperfusão, e doenças associadas com fluxo sanguíneo de músculo esquelético diminuído. a invenção também se refere às composições farmacêuticas formuladas para uso em tais métodos e aos kits para tais métodos.
BRPI0812919A 2007-06-20 2008-06-19 composição farmacêutica que compreende um composto e kit BRPI0812919B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93644007P 2007-06-20 2007-06-20
PCT/US2008/007665 WO2008156820A1 (en) 2007-06-20 2008-06-19 Short acting phenylalkylamine calcium channel blockers and uses thereof

Publications (3)

Publication Number Publication Date
BRPI0812919A2 BRPI0812919A2 (pt) 2014-10-07
BRPI0812919B1 BRPI0812919B1 (pt) 2019-01-29
BRPI0812919B8 true BRPI0812919B8 (pt) 2021-05-25

Family

ID=40156562

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812919A BRPI0812919B8 (pt) 2007-06-20 2008-06-19 composição farmacêutica que compreende um composto e kit

Country Status (18)

Country Link
US (18) US20100190852A1 (pt)
EP (1) EP2170050B1 (pt)
JP (1) JP5421908B2 (pt)
KR (1) KR101541557B1 (pt)
CN (1) CN101754678B (pt)
AU (1) AU2008266798B2 (pt)
BR (1) BRPI0812919B8 (pt)
CA (1) CA2693627C (pt)
CY (1) CY1115619T1 (pt)
DK (1) DK2170050T3 (pt)
ES (1) ES2498047T3 (pt)
HR (1) HRP20140801T1 (pt)
MX (1) MX347325B (pt)
NZ (1) NZ582033A (pt)
PL (1) PL2170050T3 (pt)
PT (1) PT2170050E (pt)
SI (1) SI2170050T1 (pt)
WO (1) WO2008156820A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX347325B (es) 2007-06-20 2017-04-12 Milestone Pharmaceuticals Inc Bloqueadores del canal de calcio de fenilalquilamina de accion corta y sus usos.
KR101052620B1 (ko) * 2008-08-28 2011-07-29 한국과학기술연구원 신규 페닐아세테이트 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 ｔ-형 칼슘 이온 채널의 활성에 의해 유발되는 질환의 예방 또는 치료용 조성물
CN102665413A (zh) * 2009-09-30 2012-09-12 微剂量治疗技术公司 治疗雷诺氏现象的方法和组合物
EP3068408A4 (en) * 2013-11-14 2017-09-06 University Medical Pharmaceuticals Corporation Microneedles for therapeutic agent delivery with improved mechanical properties
EP3283067B1 (en) * 2015-04-14 2020-01-01 Milestone Pharmaceuticals Inc. Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof
US12257224B2 (en) 2021-07-15 2025-03-25 Milestone Pharmaceuticals Inc. Methods of administration for highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker
WO2025215083A1 (en) 2024-04-10 2025-10-16 Dipharma Francis S.R.L. Method for preparing a drug used for paroxysmal supraventricular tachycardia

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1154810B (de) * 1961-04-01 1963-09-26 Knoll Ag Verfahren zur Herstellung basisch substituierter Phenylacetonitrile
US3957845A (en) * 1962-04-27 1976-05-18 Knoll A.G. Chemische Fabriken Trifluoromethyl-substituted phenyl acetonitriles
DE1493904A1 (de) * 1965-07-31 1969-06-19 Knoll Ag Verfahren zur Herstellung basisch substituierter Phenylacetonitrile
DE2059923C3 (de) * 1970-12-05 1979-01-25 Knoll Ag, 6700 Ludwigshafen l-a-Isopropyl-o-[(N-methyl-N-homoveratryl)v-aminopropyl] -3,4-dimethoxyphenylacetonitril, Verfahren zu dessen Herstellung und dieses enthaltende Arzneimittel
JPS5118940B2 (pt) 1971-12-25 1976-06-14
DE2631222C3 (de) * 1976-07-12 1979-01-04 Knoll Ag, 6700 Ludwigshafen Verfahren zur Herstellung basisch substituierter Phenylacetonitrile
DE3144150A1 (de) * 1981-04-10 1982-12-09 Basf Ag, 6700 Ludwigshafen (omega)-cyan-1,(omega)-diphenyl-azaalkan-derivate, ihre herstellung und diese enthaltende arzneimittel
DE3433383A1 (de) * 1984-09-12 1986-03-20 Boehringer Mannheim Gmbh, 6800 Mannheim Neue phenyl-acetonitril-derivate
DE3603032A1 (de) * 1986-01-31 1987-08-06 Basf Ag Basisch substituierte phenylacetonitrile, ihre herstellung und diese enthaltende arzneimittel
US4833162A (en) * 1988-02-03 1989-05-23 American Cyanamid Company Substituted benzeneacetonitriles and their use as calcium channel blockers
PT96283A (pt) 1989-12-21 1991-09-30 Searle & Co Metodos de utilizacao de 2-isopropil-2-fenilaminovaleronitrilos como imunossupressores e vasodilatadores
US5486539A (en) * 1989-12-21 1996-01-23 G. D. Searle & Co. Method of using phenylacetonitrilealkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives
US5162569A (en) * 1989-12-21 1992-11-10 G. D. Searle & Co. Phenylacetonitrilealkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives
US5247119A (en) * 1990-12-12 1993-09-21 G. D. Searle & Co. Phenylacetonitrilehydroxyalkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives
US6057344A (en) * 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
US5451604A (en) * 1993-07-26 1995-09-19 G. D. Searle & Co. Halogenated phenylacetonitrile alkylaminoalkylphenyl compounds as immunosuppressives
US5910601A (en) * 1994-09-26 1999-06-08 Darwin Discovery Limited Chiral nitriles, their preparation and their use for the manufacture of verapamil and analogues
US5859279A (en) 1996-09-10 1999-01-12 Darwin Discovery Limited Compound and process
US6750238B1 (en) 2000-05-12 2004-06-15 The University Of Toledo Aralkyl ester soft drugs
US7511077B2 (en) * 2005-02-09 2009-03-31 Neuromed Pharmaceuticals Ltd. Diamine calcium channel blockers
GB2435824A (en) 2006-03-09 2007-09-12 Esteve Labor Dr Use of nitrile compounds in the treatment of food related and other disorders
MX347325B (es) 2007-06-20 2017-04-12 Milestone Pharmaceuticals Inc Bloqueadores del canal de calcio de fenilalquilamina de accion corta y sus usos.

Also Published As

Publication number Publication date
CA2693627C (en) 2016-01-12
US20170312242A1 (en) 2017-11-02
MX347325B (es) 2017-04-12
JP2010530429A (ja) 2010-09-09
BRPI0812919B1 (pt) 2019-01-29
PL2170050T3 (pl) 2014-12-31
US10010522B2 (en) 2018-07-03
MX2009014052A (es) 2010-03-01
HRP20140801T1 (hr) 2014-11-21
CA2693627A1 (en) 2008-12-24
US20210315855A1 (en) 2021-10-14
US20230255923A1 (en) 2023-08-17
SI2170050T1 (sl) 2014-12-31
US20190380993A1 (en) 2019-12-19
US20240366552A1 (en) 2024-11-07
WO2008156820A1 (en) 2008-12-24
US20250195462A1 (en) 2025-06-19
NZ582033A (en) 2012-07-27
CN101754678B (zh) 2014-04-16
US20140296335A1 (en) 2014-10-02
US20240115543A1 (en) 2024-04-11
US20190142781A1 (en) 2019-05-16
BRPI0812919A2 (pt) 2014-10-07
EP2170050B1 (en) 2014-06-18
US9227918B2 (en) 2016-01-05
EP2170050A4 (en) 2010-11-24
JP5421908B2 (ja) 2014-02-19
PT2170050E (pt) 2014-09-04
CN101754678A (zh) 2010-06-23
AU2008266798A1 (en) 2008-12-24
KR101541557B1 (ko) 2015-08-03
US20100190852A1 (en) 2010-07-29
US9463179B2 (en) 2016-10-11
ES2498047T3 (es) 2014-09-24
US20220142963A1 (en) 2022-05-12
US20170312241A1 (en) 2017-11-02
DK2170050T3 (da) 2014-09-29
US20180280339A1 (en) 2018-10-04
HK1140913A1 (en) 2010-10-29
US20160074354A1 (en) 2016-03-17
US10010523B2 (en) 2018-07-03
CY1115619T1 (el) 2017-01-04
AU2008266798B2 (en) 2014-07-17
US20160374982A1 (en) 2016-12-29
EP2170050A1 (en) 2010-04-07
US20170312243A1 (en) 2017-11-02
US10010524B2 (en) 2018-07-03
US20210059972A1 (en) 2021-03-04
KR20100043175A (ko) 2010-04-28
US20200230097A1 (en) 2020-07-23
US9737503B2 (en) 2017-08-22

Similar Documents

Publication Publication Date Title
BRPI0812919B8 (pt) composição farmacêutica que compreende um composto e kit
BR112012031727A2 (pt) conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença.
BRPI0814737A2 (pt) Composição, métodos para reduzir, retardar ou de um outro modo inibir o crescimento e/ou replicação de hcv, para prevenir a infecção de uma célula exposta a hcv, para tratar terapeuticamente ou profilaticamente um paciente exposto ou infectado com hcv, e para tratar hepatite c, e, uso de uma composição.
CR11731A (es) Composiciones y procedimientos para su preparación y uso
DOP2008000001A (es) Oxazolidinonas substituidas y su uso
AR069490A1 (es) Agonistas de los receptores de glucocorticoides
BRPI1007379B8 (pt) composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
UY31272A1 (es) Nuevos derivados de ácido azabifenilaminobenzoico
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
ECSP10010310A (es) Nuevos compuestos y composiciones y métodos de uso
WO2009066152A3 (en) Haloallylamine inhibitors of ssao/vap-1 and uses therefor
CR20140392A (es) Dihidropirazolonas sustituidas
BRPI0507198A (pt) derivados de bisariluréia
BR112014006220A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
WO2009007412A3 (fr) Deglycation des ages
RU2012125827A (ru) Применение аналога тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции
CR20120040A (es) Derivados de 17-hidroxi-17-pentafluoroetil-estra-4,9(10)-dien-11-arilo, procedimientos para su preparación y su uso para el tratamiento de enfermedades
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
GT200900319A (es) (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea
BRPI0507895A (pt) composição para o tratamento de insuficiências venosas crÈnicas, compreendendo um extrato de folhas de videira-vermelha e um agente antiinflamatório
BRPI0510449A (pt) uso de formulações de meloxicam em medicina veterinária
BR112013010367A2 (pt) métodos de prevenir e/ou reduzir a deposição de amiloide e a doença de alzheimer, composição, uso de uma composição, agonista de tlr4 isento de endotoxina, e, uso de uma agonista de tlr4 isento de endotoxina
CL2008002060A1 (es) Compuestos derivados de sulfonamida, inhibidores de la produccion de beta amiloide; metodo de preparacion; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento de enfermedades tales como alzheimer, angiopatia amiloide, sindrome de down, entre otras.
BRPI0602397C1 (pt) composições farmacêuticas para o tratamento das doenças gordurosas do fìgado, obesidade e demais doenças associadas à sìndrome metabólica e métodos de tratamento utilizando-se as referidas composições

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/01/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/06/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF